Denali Therapeutics (NASDAQ: DNLI) insider plans 39,490-share sale

Rhea-AI Filing Summary

Denali Therapeutics insider Carole Ho has filed a Rule 144 notice to sell 39,490 shares of common stock. The shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of 801,394.26.

The shares were acquired on 02/05/2026 by exercising stock options under a registered plan for cash. In the prior three months, Carole Ho sold 150,000 common shares on 02/03/2026 for gross proceeds of 3,324,060.00 and 150,000 common shares on 02/04/2026 for gross proceeds of 3,176,970.00.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	39490	801394.26	146661833	02/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/05/2026	Exercise of options under a registered plan	Issuer			39490	02/05/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CAROLE HO 161 Oyster Point Blvd South San Francisco CA 94080	Common	02/04/2026	150000	3176970.00
CAROLE HO 161 Oyster Point Blvd South San Francisco CA 94080	Common	02/03/2026	150000	3324060.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Denali Therapeutics (DNLI) disclose?

The Form 144 discloses that insider Carole Ho intends to sell 39,490 Denali Therapeutics common shares. The planned sale will take place on NASDAQ through Morgan Stanley Smith Barney, with an indicated aggregate market value of about 801,394.26 based on the filing.

How did the Denali Therapeutics (DNLI) insider acquire the 39,490 shares to be sold?

The 39,490 Denali Therapeutics shares were acquired by exercising stock options under a registered plan on 02/05/2026. The filing states the exercise was paid in cash, and the same date is listed for both acquisition and payment of the purchase price.

Which broker will handle the planned Denali Therapeutics (DNLI) share sale?

The planned Denali Therapeutics share sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists the broker’s address as 1 New York Plaza, 8th Floor, New York, NY 10004, with the shares to be sold on the NASDAQ exchange.

What prior Denali Therapeutics (DNLI) stock sales by this insider are reported?

The filing reports that Carole Ho sold 150,000 Denali Therapeutics common shares on 02/03/2026 for gross proceeds of 3,324,060.00. It also shows another 150,000 common shares sold on 02/04/2026 for gross proceeds of 3,176,970.00.

On which exchange are the Denali Therapeutics (DNLI) shares in this Form 144 expected to trade?

The Form 144 indicates the 39,490 Denali Therapeutics common shares are expected to be sold on the NASDAQ exchange. NASDAQ is listed in the table under “Name the Securities Exchange” for this planned Rule 144 transaction.

What type of Denali Therapeutics (DNLI) security is covered by this Form 144?

The Form 144 covers common stock of Denali Therapeutics. The securities information section specifies the “Title of the Class of Securities To Be Sold” as Common, with 39,490 common shares scheduled for potential sale under Rule 144.